Metformin is associated with fewer major adverse cardiac events among patients with a new diagnosis of type 2 diabetes mellitus: A propensity score-matched nationwide study

Early type 2 diabetes mellitus (DM) may only require lifestyle modifications for glycemic control without the need for oral hypoglycemic agents (OHAs). Metformin is believed to improve cardiovascular outcomes in patients with DM, and it is considered to be a first-line therapy. However, it is unclea...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Kuang-Tso, Yeh, Yung-Hsin, Chang, Shang-Hung, See, Lai-Chu, Lee, Cheng-Hung, Wu, Lung-Sheng, Liu, Jia-Rou, Kuo, Chi-Tai, Wen, Ming-Shien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
3400
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5515773/
https://www.ncbi.nlm.nih.gov/pubmed/28700501
http://dx.doi.org/10.1097/MD.0000000000007507

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5515773/
https://www.ncbi.nlm.nih.gov/pubmed/28700501
http://dx.doi.org/10.1097/MD.0000000000007507

Ejemplares similares